| 2017 |
Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen EF, Guañabens N, Obermayer-Pietsch B, Ralston SH, Eastell R, Zillikens MC. Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone. December 2017;105:11-17. |
23 |
22 |
| 2020 |
Zarecki P, Hackl M, Grillari J, Debono M, Eastell R. Serum microRNAs as novel biomarkers for osteoporotic vertebral fractures. Bone. January 2020;130:115113. |
7 |
3 |
| 2020 |
Gossiel F, Paggiosi MA, Naylor KE, McCloskey EV, Walsh J, Peel N, Eastell R. The effect of bisphosphosphonates on bone turnover and bone balance in postmenopausal women with osteoporosis: the T-score bone marker approach in the TRIO study. Bone. February 2020;131:115158. |
1 |
0 |
| 2020 |
Schini M, Vilaca T, Poku E, Harnan S, Sutton A, Allen IE, Cummings SR, Eastell R. The risk of hip and non-vertebral fractures in patients with Parkinson's disease and parkinsonism: a systematic review and meta-analysis. Bone. March 2020;132:115173. |
1 |
0 |
| 2020 |
Ferrari S, Eastell R, Napoli N, Schwartz A, Hofbauer LC, Chines A, Wang A, Pannacciulli N, Cummings SR. Denosumab in postmenopausal women with osteoporosis and diabetes: subgroup analysis of FREEDOM and FREEDOM extension. Bone. May 2020;134:115268. |
2 |
0 |
| 2020 |
Fontalis A, Eastell R. The challenge of long-term adherence: the role of bone turnover markers in monitoring bisphosphonate treatment of osteoporosis. Bone. July 2020;136:115336. |
0 |
0 |
| 2020 |
Vilaca T, Schini M, Harnan S, Sutton A, Poku E, Allen IE, Cummings SR, Eastell R. The risk of hip and non-vertebral fractures in type 1 and type 2 diabetes: a systematic review and meta-analysis update. Bone. August 2020;137:115457. |
18 |
16 |
| 2020 |
Gossiel F, Eastell R. Response to letter relating to Gossiel F, paggiosi MA, Naylor KE, et al. The effect of bisphosphosphonates on bone turnover and bone balance in postmenopausal women with osteoporosis: the T-score bone marker approach in the TRIO study. Bone. August 2020;137:115430. |
0 |
0 |
| 2020 |
Schini M, Nicklin P, Eastell R. Establishing race-, gender- and age-specific reference intervals for pyridoxal 5′-phosphate in the NHANES population to better identify adult hypophosphatasia. Bone. December 2020;141:115577. |
2 |
1 |
| 2021 |
Salam S, Gallagher O, Hughes D, Khwaja A, Eastell R. The role of static bone histomorphometry in diagnosing renal osteodystrophy. Bone. January 2021;142:115689. |
0 |
0 |
| 2021 |
Salam S, Gallagher O, Gossiel F, Paggiosi M, Eastell R, Khwaja A. Vascular calcification relationship to vascular biomarkers and bone metabolism in advanced chronic kidney disease. Bone. February 2021;143:115699. |
0 |
0 |
| 2021 |
Desborough R, Nicklin P, Gossiel F, Balasubramanian M, Walsh JS, Petryk A, Teynor M, Eastell R. Clinical and biochemical characteristics of adults with hypophosphatasia attending a metabolic bone clinic. Bone. March 2021;144:115795. |
3 |
3 |
| 2022 |
Black DM, Condra K, Adams AL, Eastell R. Bisphosphonates and the risk of atypical femur fractures. Bone. March 2022;156:116297. |
0 |
0 |
| 2022 |
Mattia L, Davis S, Mark-Wagstaff C, Abrahamsen B, Peel N, Eastell R, Schini M. Utility of PINP to monitor osteoporosis treatment in primary care, the POSE study (PINP and Osteoporosis in Sheffield Evaluation). Bone. May 2022;158:116347. |
1 |
1 |
| 2023 |
Eastell R, Russell RGG. Introduction to the bisphosphonate special issue. Bone. July 2023;172:116754. |
0 |
0 |
| 2021 |
Cavalier E, Eastell R, Jørgensen NR, Makris K, Tournis S, Vasikaran S, Kanis JA, Cooper C, Pottel H, Morris HA; IFCC-IOF Committee for Bone Metabolism (C-BM). A multicenter study to evaluate harmonization of assays for -terminal telopeptides of type I collagen (ß-CTX): a report from the IFCC-IOF committee for bone metabolism (C-BM) [published correction appears in Calcif Tiss Int. June 2021;108(6):825-826]. Calcif Tiss Int. June 2021;108(6):785-797. |
0 |
0 |
| 2021 |
Cavalier E, Eastell R, Jørgensen NR, Makris K, Tournis S, Vasikaran S, Kanis JA, Cooper C, Pottel H, Morris HA. Correction to: a multicenter study to evaluate harmonization of assays for C-terminal telopeptides of type I collagen (ß-CTX): a report from the IFCC-IOF committee for bone metabolism (C-BM). Calcif Tiss Int. June 2021;108(6):825-826. |
0 |
0 |
| 1990 |
Eriksen EF, Hodgson SF, Eastell R, Cedel SL, O'Fallon WM, Riggs BL. Cancellous bone remodeling in type I (postmenopausal) osteoporosis: quantitative assessment of rates of formation, resorption, and bone loss at tissue and cellular levels. J Bone Miner Res. April 1990;5(4):311-319. |
43 |
36 |
| 1991 |
Eastell R, Cedel SL, Wahner HW, Riggs BL, Melton LJ III. Classification of vertebral fractures. J Bone Miner Res. March 1991;6(3):207-215. |
45 |
37 |
| 2003 |
Eastell R, Barton I, Hannon R, Chines A, Garnero P, Delmas P. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res. June 2003;18(6):1051-1056. |
28 |
23 |
| 2005 |
Delmas PD, van de Langerijt L, Watts NB, Eastell R, Genant H, Grauer A, Cahall DL; IMPACT Study Group. Underdiagnosis of vertebral fractures is a worldwide problem: the IMPACT study. J Bone Miner Res. April 2005;20(4):557-563. |
23 |
22 |
| 2012 |
Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, Cummings SR, Hue TF, Lippuner K, Lakatos P, Leung PC, Man Z, Martinez RLM, Tan M, Ruzycky ME, Su G, Eastell R. The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. February 2012;27(2):243-254. |
24 |
18 |
| 2015 |
Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S, Watts NB, Brandi ML, Peters E, Guise T, Eastell R, Cheung AM, Morin SN, Masri B, Cooper C, Morgan SL, Obermayer-Pietsch B, Langdahl BL, Al Dabagh R, Davison KS, Kendler DL, Sándor GK, Josse RG, Bhandari M, El Rabbany M, Pierroz DD, Sulimani R, Saunders DP, Brown JP, Compston J; International Task Force on Osteonecrosis of the Jaw. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. January 2015;30(1):3-23. |
39 |
23 |
| 2015 |
Evans AL, Paggiosi MA, Eastell R, Walsh JS. Bone density, microstructure and strength in obese and normal weight men and women in younger and older adulthood. J Bone Miner Res. May 2015;30(5):920-928. |
21 |
19 |
| 2018 |
Cummings SR, Ferrari S, Eastell R, Gilchrist N, Jensen J-EB, McClung M, Roux C, Törring O, Valter I, Wang AT, Brown JP. Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res. February 2018;33(2):190-198. |
35 |
27 |
| 2019 |
Ebeling PR, Akesson K, Bauer DC, Buchbinder R, Eastell R, Fink HA, Giangregorio L, Guanabens N, Kado D, Kallmes D, Katzman W, Rodriguez A, Wermers R, Wilson HA, Bouxsein ML. The efficacy and safety of vertebral augmentation: a second ASBMR task force report. J Bone Miner Res. 2019;34(1):3-21. |
6 |
3 |
| 2019 |
Bouxsein ML, Eastell R, Lui L-Y, Wu LA, de Papp AE, Grauer A, Marin F, Cauley JA, Bauer DC, Black DM; FNIH Bone Quality Project. Change in bone density and reduction in fracture risk: a meta-regression of published trials. J Bone Miner Res. April 2019;34(4):632-642. |
27 |
22 |
| 2019 |
Bouxsein ML, Eastell R, Liu L, Wu LA, Papp AEd, Grauer A, Marin F, Cauley JA, Bauer DC, Black DM; FNIH Bone Quality Project. Reply to: change in bone density and reduction in fracture risk: a meta‐regression of published trials. J Bone Miner Res. October 2019;34(10):1977-1978. |
1 |
1 |
| 2020 |
Buchbinder R, Ebeling PR, Akesson K, Bauer DC, Eastell R, Fink HA, Giangregorio L, Guanabens N, Kado D, Kallmes D, Katzman W, Rodriguez A, Wermers R, Wilson HA, Bouxsein ML. Response to: some questions about the article "the efficacy and safety of vertebral augmentation: a second ASBMR task force report". J Bone Miner Res. January 2020;35(1):212-213. |
0 |
0 |
| 2020 |
Chotiyarnwong P, McCloskey E, Eastell R, McClung MR, Gielen E, Gostage J, McDermott M, Chines A, Huang S, Cummings SR. A pooled analysis of fall incidence from placebo‐controlled trials of denosumab. J Bone Miner Res. June 2020;35(6):1014-1021. |
1 |
1 |
| 2020 |
Napoli N, Conte C, Eastell R, Ewing SK, Bauer DC, Strotmeyer ES, Black DM, Samelson EJ, Vittinghoff E, Schwartz AV. Bone turnover markers do not predict fracture risk in Type 2 diabetes. J Bone Miner Res. December 2020;35(12):2363-2371. |
3 |
1 |
| 2021 |
Eastell R, Black DM, Lui L, Chines A, Marin F, Khosla S, de Papp AE, Cauley JA, Mitlak B, McCulloch CE, Vittinghoff E, Bauer DC; Foundation for the National Institutes of Health (FNIH) Bone Quality Project. Treatment‐related changes in bone turnover and fracture risk reduction in clinical trials of antiresorptive drugs: proportion of treatment effect explained. J Bone Miner Res. February 2021;36(2):236-243. |
0 |
0 |
| 2021 |
Ramchand SK, David NL, Lee H, Eastell R, Tsai JN, Leder BZ. Efficacy of zoledronic acid in maintaining areal and volumetric bone density after combined denosumab and teriparatide administration: DATA-HD study extension. J Bone Miner Res. May 2021;36(5):921-930. |
1 |
0 |
| 2021 |
Vilaca T, Paggiosi M, Walsh JS, Selvarajah D, Eastell R. The effects of type 1 diabetes and diabetic peripheral neuropathy on the musculoskeletal system: a case–control study. J Bone Miner Res. June 2021;36(6):1048-1059. |
2 |
2 |
| 2022 |
Eastell R, Vittinghoff E, Lui L-Y, McCulloch CE, Pavo I, Chines A, Khosla S, Cauley JA, Mitlak B, Bauer DC, Bouxsein M, Black DM. Validation of the surrogate threshold effect for change in bone mineral density as a surrogate endpoint for fracture outcomes: the FNIH-ASBMR SABRE project. J Bone Miner Res. January 2022;37(1):29-35. |
5 |
3 |
| 2022 |
Vilaca T, Velmurugan N, Smith C, Abrahamsen B, Eastell R. Osteomalacia as a complication of intravenous iron infusion: a systematic review of case reports. J Bone Miner Res. June 2022;37(6):1188-1199. |
0 |
0 |
| 2022 |
Farzi M, Pozo JM, McCloskey E, Eastell R, Harvey NC, Frangi AF, Wilkinson JM. Quantitating age-related BMD textural variation from DXA region-free-analysis: a study of hip fracture prediction in three cohorts. J Bone Miner Res. September 2022;37(9):1679-1688. |
1 |
1 |
| 2022 |
Eastell R, Vittinghoff E, Lui L-Y, Ewing SK, Schwartz AV, Bauer DC, Black DM, Bouxsein ML. Diabetes mellitus and the benefit of antiresorptive therapy on fracture risk. J Bone Miner Res. November 2022;37(11):2121-2131. |
0 |
0 |
| 2022 |
Perri G, Hill TR, Mathers JC, Walsh JS, Gossiel F, Winther K, Frölich J, Folkestad L, Cold S, Eastell R. Long-term selenium-yeast supplementation does not affect bone turnover markers: a randomized placebo-controlled trial. J Bone Miner Res. November 2022;37(11):2165-2173. |
0 |
0 |
| 2022 |
Fuleihan GE-H, Chakhtoura M, Cipriani C, Eastell R, Karonova T, Liu J-M, Minisola S, Mithal A, Moreira CA, Peacock M, Schini M, Silva B, Walker M, El Zein O, Marcocci C. Classical and nonclassical manifestations of primary hyperparathyroidism. J Bone Miner Res. November 2022;37(11):2330-2350. |
3 |
2 |
| 2019 |
Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. May 2019;104(5):1595-1622. |
23 |
20 |
| 2017 |
Eastell R, Szulc P. Use of bone turnover markers in postmenopausal osteoporosis. Lancet Diabetes Endocrinol. November 2017;5(11):908-923. |
16 |
13 |
| 2012 |
Estrada K, Styrkarsdottir U, Evangelou E, Hsu Y-H, Duncan EL, Ntzani EE, Oei L, Albagha OME, Amin N, Kemp JP, Koller DL, Li G, Liu C-T, Minster RL, Moayyeri A, Vandenput L, Willner D, Xiao S-M, Yerges-Armstrong LM, Zheng H-F, Alonso N, Eriksson J, Kammerer CM, Kaptoge SK, Leo PJ, Thorleifsson G, Wilson SG, Wilson JF, Aalto V, Alen M, Aragaki AK, Aspelund T, Center JR, Dailiana Z, Duggan DJ, Garcia M, Garcia-Giralt N, Giroux S, Hallmans G, Hocking LJ, Husted LB, Jameson KA, Khusainova R, Kim GS, Kooperberg C, Koromila T, Kruk M, Laaksonen M, Lacroix AZ, Lee SH, Leung PC, Lewis JR, Masi L, Mencej-Bedrac S, Nguyen TV, Nogues X, Patel MS, Prezelj J, Rose LM, Scollen S, Siggeirsdottir K, Smith AV, Svensson O, Trompet S, Trummer O, van Schoor NM, Woo J, Zhu K, Balcells S, Brandi ML, Buckley BM, Cheng S, Christiansen C, Cooper C, Dedoussis G, Ford I, Frost M, Goltzman D, González-Macías J, Kähönen M, Karlsson M, Khusnutdinova E, Koh J-M, Kollia P, Langdahl BL, Leslie WD, Lips P, Ljunggren Ö, Lorenc RS, Marc J, Mellström D, Obermayer-Pietsch B, Olmos JM, Pettersson-Kymmer U, Reid DM, Riancho JA, Ridker PM, Rousseau F, Slagboom PE, Tang NLS, Urreizti R, Van Hul W, Viikari J, Zarrabeitia MT, Aulchenko YS, Castano-Betancourt M, Grundberg E, Herrera L, Ingvarsson T, Johannsdottir H, Kwan T, Li R, Luben R, Medina-Gómez C, Palsson ST, Reppe S, Rotter JI, Sigurdsson G, van Meurs JBJ, Verlaan D, Williams FMK, Wood AR, Zhou Y, Gautvik KM, Pastinen T, Raychaudhuri S, Cauley JA, Chasman DI, Clark GR, Cummings SR, Danoy P, Dennison EM, Eastell R, Eisman JA, Gudnason V, Hofman A, Jackson RD, Jones G, Jukema JW, Khaw K-T, Lehtimäki T, Liu Y, Lorentzon M, McCloskey E, Mitchell BD, Nandakumar K, Nicholson GC, Oostra BA, Peacock M, Pols HAP, Prince RL, Raitakari O, Reid IR, Robbins J, Sambrook PN, Sham PC, Shuldiner AR, Tylavsky FA, van Duijn CM, Wareham NJ, Cupples LA, Econs MJ, Evans DM, Harris TB, Kung AWC, Psaty BM, Reeve J, Spector TD, Streeten EA, Zillikens MC, Thorsteinsdottir U, Ohlsson C, Karasik D, Richards JB, Brown MA, Stefansson K, Uitterlinden AG, Ralston SH, Ioannidis JPA, Kiel DP, Rivadeneira F. Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet. April 15, 2012;44(5):491-501. |
39 |
18 |
| 2001 |
McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Wasnich RD, Greenwald M, Kaufman J-M, Chesnut CH, Reginster J-Y; Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women: Hip Intervention Program Study Group. NEJM. February 1, 2001;344(5):333-340. |
71 |
54 |
| 2007 |
Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR; HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. NEJM. May 3, 2007;356(18):1809-1822. |
90 |
66 |
| 2009 |
Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C; FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. NEJM. August 20, 2009;361(8):756-765. |
133 |
102 |
| 1993 |
Melton LJ III, Lane AW, Cooper C, Eastell R, O'Fallon WM, Riggs BL. Prevalence and incidence of vertebral deformities. Osteoporos Int. May 1993;3(3):113-119. |
28 |
22 |
| 2000 |
Reginster J-Y, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R; Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int. January 2000;11(1):83-91. |
72 |
61 |
| 2000 |
Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J; Committee of Scientific Advisors of the International Osteoporosis Foundation. The use of biochemical markers of bone turnover in osteoporosis. Osteoporos Int. December 2000;11(suppl 6):S2-S17. |
23 |
17 |
| 2011 |
Vasikaran S, Eastell R, Bruyère O, Foldes AJ, Garnero P, Griesmacher A, McClung M, Morris HA, Silverman S, Trenti T, Wahl DA, Cooper C, Kanis JA; OF-IFCC Bone Marker Standards Working Group. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int. February 2011;22(2):391-420. |
41 |
31 |
| 2020 |
Vasikaran SD, Bhattoa HP, Eastell R, Heijboer AC, Jørgensen NR, Makris K, Ulmer C, Kanis JA, Cooper C, Silverman S, Cavalier E. Harmonization of commercial assays for PINP: the way forward. Osteoporos Int. March 2020;31(3):409-412. |
2 |
0 |
| 2020 |
Paggiosi MA, Debono M, Walsh JS, Peel NFA, Eastell R. Quantitative computed tomography discriminates between postmenopausal women with low spine bone mineral density with vertebral fractures and those with low spine bone mineral density only: the SHATTER study. Osteoporos Int. April 2020;31(4):667-675. |
1 |
1 |
| 2020 |
Cummings SR, Eastell R. Stop (mis)classifying fractures as high- or low-trauma or as fragility fractures. Osteoporos Int. June 2020;31(6):1023-1024. |
7 |
5 |
| 2021 |
Lane NE, Saag K, O’Neill TJ, Manion M, Shah R, Klause U, Eastell R. Correction to: real-world bone turnover marker use: impact on treatment decisions and fracture. Osteoporos Int. March 2021;32(3):609-609. |
0 |
0 |
| 2021 |
Cummings SR, Eastell R. Authors’ response to KD Stathopoulos regarding "stop (mis)classifying fractures as high or low trauma or as fragility fractures". Osteoporos Int. April 2021;32(4):781-781. |
0 |
0 |
| 2021 |
Lane NE, Saag K, O’Neill TJ, Manion M, Shah R, Klause U, Eastell R. Real-world bone turnover marker use: impact on treatment decisions and fracture [published correction appears in Osteoporos Int. March 2021;32(3):609-609]. Osteoporos Int. May 2021;32(5):831-840. |
0 |
0 |